Data

The NEURAPRO-E: A comparison study of fish oil capsules and psychological therapy versus placebo capsules and psychological therapy in patients at risk of developing a psychotic disorder.

Health Data Australia Contributor Records
McGorry, Patrick ; Mental Health Node
Viewed: [[ro.stat.viewed]] Cited: [[ro.stat.cited]] Accessed: [[ro.stat.accessed]]
ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Adc&rfr_id=info%3Asid%2FANDS&rft_id=info:doi10.26187/ZZ44-5H24&rft.title=The NEURAPRO-E: A comparison study of fish oil capsules and psychological therapy versus placebo capsules and psychological therapy in patients at risk of developing a psychotic disorder.&rft.identifier=http://doi.org/10.26187/ZZ44-5H24&rft.publisher=Orygen&rft.description=Dataset derived from a clinical research study focusing on the early intervention in the prodromal phase of psychotic disorders, where individuals exhibit symptoms indicative of psychosis but not severe enough to constitute a full disorder. The study involved 320 patients identified as 'ultra high risk' (UHR) for developing psychotic disorders based on established criteria. Participants were randomized to receive either omega-3 fatty acids or a placebo, alongside a standard psychological treatment called cognitive behavioural case management (CBCM). CBCM combines elements of traditional case management with cognitive behavioural therapy, commonly used in clinical settings. The primary objective of this research was to evaluate whether omega-3 fatty acids, against a backdrop of CBCM, can lower the incidence of developing a psychotic disorder among these at-risk individuals.&rft.creator=McGorry, Patrick &rft.creator=Mental Health Node &rft.date=2017&rft.relation=www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=ACTRN12608000475347&rft_subject=FOR: Mental Health&rft.type=dataset&rft.language=English Access the data

Full description

Dataset derived from a clinical research study focusing on the early intervention in the prodromal phase of psychotic disorders, where individuals exhibit symptoms indicative of psychosis but not severe enough to constitute a full disorder. The study involved 320 patients identified as 'ultra high risk' (UHR) for developing psychotic disorders based on established criteria. Participants were randomized to receive either omega-3 fatty acids or a placebo, alongside a standard psychological treatment called cognitive behavioural case management (CBCM). CBCM combines elements of traditional case management with cognitive behavioural therapy, commonly used in clinical settings. The primary objective of this research was to evaluate whether omega-3 fatty acids, against a backdrop of CBCM, can lower the incidence of developing a psychotic disorder among these at-risk individuals.

Notes

HeSANDA 1.0.0

This dataset is part of a larger collection

Click to explore relationships graph
Subjects

User Contributed Tags    

Login to tag this record with meaningful keywords to make it easier to discover

Identifiers